CRF Design & Utilization - UKM Medical Centre
CRF Design & Utilization - UKM Medical Centre
CRF Design & Utilization - UKM Medical Centre
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
GCP Course<br />
Pusat Perubatan <strong>UKM</strong><br />
Kuala Lumpur<br />
T Mahendran<br />
Consultant, <strong>Medical</strong> Affairs<br />
SS Inter Pharma Consultants<br />
Kuala Lumpur, Malaysia<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 1
ICH GCP<br />
• 8 Sections covering the<br />
• principal participants<br />
and responsibilities<br />
• ethics committees<br />
• investigator<br />
• sponsor incl. monitor<br />
• principal procedures<br />
• designing<br />
• conducting<br />
• recording<br />
• reporting<br />
of clinical<br />
studies<br />
• main paperwork<br />
• main terms<br />
• clinical study protocol<br />
• investigator’s brochure<br />
• clinical study report<br />
• essential documents<br />
glossary including 62 terms from<br />
adverse drug reaction to wellbeing<br />
of trial subjects<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 2
Case Report Forms (<strong>CRF</strong>) <strong>Design</strong><br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 3
What‟s A <strong>CRF</strong>?<br />
A Case Report Form (or <strong>CRF</strong>) is the tool<br />
used to collect data; it can be a paper- or<br />
electronic-based questionnaire specifically<br />
used in a clinical trial/research.<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 4
Purpose of the <strong>CRF</strong><br />
• Collection of relevant data in a specific format<br />
• As per protocol<br />
• In compliance with all regulatory requirements<br />
• Allows for efficient and complete data processing,<br />
analysis and reporting<br />
• Facilitates the exchange of data across projects and<br />
organizations esp. through standardization<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong>
Relationship of <strong>CRF</strong> to Protocol<br />
• Protocol determines what data should<br />
be collected in the <strong>CRF</strong><br />
• All data specified in the protocol must<br />
be collected in the <strong>CRF</strong><br />
• Data that will not be analyzed should<br />
not appear in the <strong>CRF</strong><br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong>
<strong>CRF</strong> <strong>Design</strong> & Development Process<br />
Involvement of all Stakeholders<br />
• Project Clinician/<strong>Medical</strong> Director<br />
• Clinical Research Associate (CRA)<br />
• Statistician<br />
• Database Programmer<br />
• Data Manager<br />
• Others<br />
• Standards, Dictionary Coding,<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong>
Poorly <strong>Design</strong>ed <strong>CRF</strong>s<br />
• Garbage In = Garbage Out<br />
• Data not collected<br />
• Database may require modification<br />
• Need to edit data<br />
• Target dates are missed<br />
• Over-collection of (irrelevant) data –<br />
resources wasted in collecting & processing<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong>
<strong>CRF</strong> <strong>Design</strong> Overview<br />
in Industry<br />
• Harmonization of recording patient data<br />
• Process of creating <strong>CRF</strong>s<br />
• <strong>CRF</strong> layout<br />
• General structure<br />
• Individual modules (building blocks of <strong>CRF</strong>)<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 9
Harmonized <strong>CRF</strong> Modules<br />
acc. to Sponsor Standards<br />
Standard Templates exist for the following <strong>CRF</strong> Modules:<br />
• Informed Consent (incl. Contraception/Pregnancy)<br />
• Demographic Data<br />
• Physical Examination<br />
• Vital Signs/ECG<br />
• <strong>Medical</strong> History<br />
• Laboratory/Urinalysis<br />
• Adverse Events<br />
• Concomitant Medication<br />
• Study Medication<br />
• Termination Section<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 10
<strong>CRF</strong> <strong>Design</strong><br />
• Harmonization (bringing in agreement) of<br />
individual components of <strong>CRF</strong><br />
= agreement on systematic way of asking<br />
for patient data<br />
• Use of standard templates and modules<br />
• <strong>Design</strong>-Tool: QuarkXPress (a professional<br />
layout all program)<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 11
Path from<br />
study<br />
information<br />
(protocol) to<br />
printed <strong>CRF</strong><br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 12
Protocol<br />
<strong>CRF</strong>-<strong>Design</strong><br />
5 days<br />
<strong>CRF</strong> <strong>Design</strong> & Review<br />
Timelines<br />
<strong>CRF</strong>-<strong>Design</strong> +<br />
Data Management<br />
5 days<br />
Delivery<br />
1st Draft *<br />
Final<br />
Working<br />
Draft *<br />
Final<br />
Draft for<br />
Proof<br />
Printing<br />
Proof<br />
Print<br />
Final<br />
Print<br />
<strong>CRF</strong> Development<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 13
Overview<br />
Cover and Spine<br />
(Pantoprazole)<br />
cover and spine<br />
layout version of<br />
licenced product<br />
- phase IV study<br />
Confidentiality<br />
Barcode<br />
on all NCR pages for<br />
scanning of pages<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 14
Layout of <strong>CRF</strong>-Pages<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 15
Study Schedule/<br />
Overview<br />
‣ Time-saving quick<br />
reference<br />
‣ Outlines all study<br />
specific procedures<br />
‣ Indicates what to be<br />
done at which visit<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 16
Order of Sections<br />
General Structure of <strong>CRF</strong>s<br />
Visits (e.g. B0 – T12, V0 – V4)<br />
<strong>Medical</strong> History<br />
Planned Surgeries<br />
Adverse Events<br />
Concomitant Medication<br />
Study Medication<br />
Termination Section<br />
Serious Adverse Event Reporting Form<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 17
<strong>CRF</strong> Contents<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 18
Informed Consent / In-/Exclusion Criteria<br />
First of all....<br />
Patient IC<br />
Inclusion<br />
criteria<br />
Exclusion<br />
criteria<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 19
Demographic Data<br />
• Date of birth<br />
• Gender<br />
• Height<br />
• Weight<br />
• Race Asian<br />
Black<br />
White<br />
Other<br />
• Smoking<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 20
Physical Examination<br />
(Initial Visit / Termination Visit)<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 21
Changes in Medication / AE<br />
T4<br />
CM<br />
AE<br />
SM<br />
AE<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 22
<strong>Medical</strong> History<br />
• Study indication (e.g. asthma)<br />
preprinted, if applicable<br />
• Definition of "relevant previous"<br />
is study specific<br />
• Please check with section<br />
"Planned surgeries" because the<br />
underlying disease/diagnosis has<br />
to be entered here.<br />
• In case a diagnosis is deleted,<br />
please don't renumber.<br />
Reason: link to CM<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 23
Planned Surgeries / Invasive Procedures<br />
Enter name<br />
of planned<br />
surgery /<br />
procedure<br />
Enter actual<br />
date of event<br />
(or tick if not<br />
performed)<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 24
Adverse Events<br />
• Do not change the number of the AE<br />
• Please enter one diagnosis. If no<br />
diagnosis is available but only<br />
symptoms, for each symptom a<br />
separate AE form has to be filled in<br />
(e.g. nausea and vomiting)<br />
Reason: only one symptom can be<br />
coded.<br />
• Final outcome "unknown", please<br />
check, when collecting the <strong>CRF</strong>s<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
• Don't forget the mandatory comment<br />
on causality assessment.<br />
29/11/2011 25
Relevant Previous and Concomitant Medication<br />
MH<br />
AE<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 26
Study Medication<br />
• Study specific form<br />
• Mandatory:<br />
- Study medication (preprinted)<br />
- Start date<br />
- Stop date<br />
• Optional:<br />
- Study Period<br />
- Recording of returned medication<br />
- Dosage (frequency, strength)<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 27
Section T<br />
Extended by central<br />
safety tests (Laboratory<br />
test, ECG etc.)<br />
Premature discontinuation:<br />
Mandatory and optional reasons<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 28
Case Report Form (<strong>CRF</strong>) <strong>Utilization</strong><br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 29
ICH GCP<br />
• 8 Sections covering the<br />
• principal participants<br />
and responsibilities<br />
• ethics committees<br />
• investigator<br />
• sponsor incl. monitor<br />
• principal procedures<br />
• designing<br />
• conducting<br />
• recording<br />
• reporting<br />
of clinical<br />
studies<br />
• main paperwork<br />
• main terms<br />
• clinical study protocol<br />
• investigator’s brochure<br />
• clinical study report<br />
• essential documents<br />
glossary including 62 terms from<br />
adverse drug reaction to wellbeing<br />
of trial subjects<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 30
General Completion Instructions<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 31
Baseline visit B0<br />
• Informed<br />
consent<br />
has to be<br />
available<br />
• Inclusion/<br />
exclusion<br />
criteria<br />
check<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 32
Baseline visit B0<br />
No initials will be<br />
recorded in the<br />
<strong>CRF</strong> !<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 33
Baseline visit B0<br />
No entry<br />
necessary if<br />
„Others‟ is<br />
without findings<br />
No ECG entry!<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 34
Baseline visit B0<br />
Enter “Not Known”<br />
(NK) if data not<br />
available<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 35
Baseline visit B0 (B1 – B4)<br />
Within 1.5 h vs.<br />
anticipated time of T0<br />
Multiply predicted value acc.<br />
to Quanjer table with factor<br />
0.9 (if patient is non-european<br />
or non-caucasian)<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 36
Baseline visit B1<br />
verification of<br />
B0 lab results,<br />
if applicable<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 37
Baseline visit B1 (B2, B3, B4)<br />
x<br />
x<br />
Randomization<br />
criteria fulfilled<br />
=> go to T0<br />
x<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 38
Treatment visit T0<br />
Baseline period >2 weeks:<br />
Laboratory test<br />
Urinalysis<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 39
<strong>Medical</strong> history<br />
Diagnoses/<br />
diseases in the<br />
last 6 months<br />
prior to B0<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 40
Adverse events<br />
„yes‟ or „no‟<br />
to be ticked<br />
Final outcome<br />
to be entered<br />
also for FU<br />
Causality assessment<br />
should be given in any case!<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 41
Concomitant Medication<br />
Combination<br />
drugs – only trade<br />
names!<br />
Formulations as<br />
exact as possible<br />
Rescue<br />
medication<br />
(salbutamol)<br />
to be recorded<br />
only once<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
Strength of smallest unit<br />
29/11/2011 42
Study termination/Discontinuation report<br />
includes:<br />
• Physical examination<br />
• Vital signs<br />
• ECG<br />
• Laboratory investigations (no urinalysis)<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 43
Study termination/Discontinuation report<br />
Please check protocol<br />
for discontinuation criteria<br />
(chapter 13.1)<br />
Sign & date after<br />
last study-related<br />
activity<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 44
Thank you for your attention!<br />
~~~ Questions ~~~<br />
T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />
29/11/2011 45